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Comment on ‘Cancer genetic
counselling’ by P. Mandich et al.
(Ann Oncol 2005; 16: 171)
With the advent of genetic tests, genetic counselling is attract-
ing increasing attention, as also shown by the recent letter by
Mandich et al. [1], which addressed some aspects of our
oncologist-based multistep model of cancer genetic counsel-
ling [2]. Perhaps the features of our model can be appreciated
if we explain the rationale that prompted it. The philosophy
and practice of the model emerged from a clinical oncological
setting [2]. It was specifically designed to meet the user’s
needs of physical, mental and social well-being as rec-
ommended by the WHO [3], and is in keeping with the Italian
National Health Plan in force when the model was designed,
in that it empowers users to make an informed, fully aware
choice among the various preventive, diagnostic and thera-
peutic options available [4]. The model, which employs an
interdisciplinary team, identifies and manages at-risk subjects,
and promotes the early diagnosis of invasive and preinvasive
hereditary and familial tumours.
Pedigree construction and genetic testing (T1) occur only
when the user is fully empowered to decide whether he/she
wishes to know their cancer risk. Decisional empowerment
derives from extensive information-giving about all aspects of
familial or hereditary cancer (T0). At this step, the counsellor
also obtains all the information necessary, including clinical-
pathological files, to construct the pedigree and to estimate
risk, thereby avoiding piecemeal data collection that would
delay risk estimation. Communication modalities are geared to
the user’s educational/cultural level and their motivations and
expectations in requesting counselling. The oncologist defines
the user’s risk profile (hereditary, familial or personal) and
informs them of the possibility, limits and implications, also
for their family, of risk estimation, and of prevention options
so that the user can decide whether to proceed or not with
counselling. At crucial steps of counselling, the psycho-oncol-
ogist evaluates also the user’s coping style, which is an indi-
cator of psychological well being [5]. A grave cognitive
deficit and a severe psychopathologic condition preclude con-
tinuation of counselling because fully aware consent (i.e.
‘empowerment’) and not just informed consent is required to
proceed from step to step of the model. The counsellor verifies
acquisition of information by questioning the user. The coun-
sellor–user relationship is considered a partnership in which a
dynamic feedback of information from and to the user is
established. Gene testing is not appropriate for everyone [6].
Not all users have a genetic risk.
Given the high psychological impact of cancer, global
counselling is particularly important and requires the specific
professional figures in the field of hereditary and familial can-
cer. It is conceivable that, given their training and daily
exposure to patients, oncologists are able to estimate personal
risk, to propose diagnostic/therapeutic strategies and to explain
these to the user considering their healthy or disease status.
The multistep counselling model, endorsed by the Italian
National Health Service for application in patient care, is
being used in some centers of the Network for Hereditary
Breast and Ovarian Cancer. Information provided by the
media or on educational websites, even when ‘officially’ sanc-
tioned, needs to be ‘interpreted’ by the health professional
according to each user’s needs.
In conclusion, our multistep model is not intended to
replace classical genetic counselling, but rather to provide an
alternative that fosters the oncologist–user partnership in
order to promote early diagnosis and prevention.
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Does the concurrent use of
anthracycline and granulocyte
colony-stimulating factor influence
the risk of secondary leukaemia in
breast cancer women?
Topoisomerase II inhibitors and alkylating agents induce sec-
ondary acute leukaemia (sAL) differently. The risk of this
complication peaks 5–10 years after the start of chemotherapy
in patients receiving alkylating agents. These patients fre-
quently present with myelodysplasia (MDS), which may then
progress to overt acute myeloid leukaemia (AML). Unlike the
sAL associated with alkylating agents, that induced by anthra-
cylines is monocytic, involves a specific cytogenetic abnorm-
ality (11q23) and develops within a few years (generally 2–3
years) after treatment, without prior MDS in some cases [1].
Although granulocyte colony-stimulating factor (G-CSF)
induced the growth of primary acute myeloid leukaemic blasts
in vitro in about 50% of cases, it was not leukaemogenic and
even had an antileukaemic effect in some preclinical models
[2]. In early breast cancer, Crump et al. [3] found no cases of
sAL among patients given epirubicin-based adjuvant che-
motherapy plus G-CSF, and Citron et al. [4] reported no cor-
relation between the use of G-CSF and the incidence of sAL
among 2005 patients randomized to standard or dose-dense
chemotherapy. Conversely, in the cross-protocol analysis on
six complete NSABP trials with different regimens of anthra-
cycline and cyclophosphamide, Smith et al. found a positive
association between the use and the dose of G-CSF and the
risk of sAL in patients receiving standard anthracycline and
dose-intensified cyclophosphamide [5]; the estimated risk of
AML/MDS was 3.58 for patients given more than the median
dose of G-CSF (242mg/kg).
A total of 497 evaluable stage I–II breast cancer patients
were randomly assigned to receive epirubicin 120 mg/m2 and
cyclophosphamide 600 mg/m2 i.v. (hEC) on day 1 every 21
days for four cycles with or without lonidamine and with or
without prophylactic G-CSF according to a factorial 2 2
design [6]. Among these patients we encountered, at median
follow-up of 55 months, a 58-year-old woman who developed
AML (monocytic, M5) 19 months after completion of che-
motherapy. She had received filgrastim (480mg/day s.c) every
other day on days 8, 10, 12 and 14 of each hEC course and
chest-wall irradiation (50 Gy plus a boost of 10 Gy) after com-
pletion of chemotherapy. She died 10 days after diagnosis of
sAL. Although the cumulative epirubicin dose (480 mg/m2)
was less than that reported by Crump et al. [3], we found no
other cases of sAL among the 243 evaluable patients in our
series receiving hEC without G-CSF. Thus the crude incidence
of sAL after adjuvant hEC with G-CSF support was 0.41%.
The case presented here and the recent update on the inci-
dence of sAL after adjuvant chemotherapy for early breast
cancer deserve some consideration. Several studies have
demonstrated the possibility of achieving a modest to moder-
ate increase in dose intensity using growth factors as an
adjunct to higher-dose or dose-dense chemotherapy regimens,
which were able to improve the clinical outcome. However,
since the dose intensity of anticancer therapy has increased in
parallel with the introduction of G-CSF in current clinical
practice, distinguishing the contribution of intensified therapy
versus G-CSF is often difficult. Above all, the leukaemogenic
hazards of cancer treatment should always be weighed against
its therapeutic benefits. Considering the recent development of
indications even for subgroups of patients at moderate risk of
relapse, it is crucial to balance the absolute survival benefit
against the risk of severe complications caused by chemother-
apy itself, particularly secondary acute leukaemia. In con-
clusion, this single case cannot prove the role of G-CSF in the
development of sAL, but does point out the importance of
being prudent when prescribing high-dose chemotherapy with
growth factor support.
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